<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03189446</url>
  </required_header>
  <id_info>
    <org_study_id>7964</org_study_id>
    <nct_id>NCT03189446</nct_id>
  </id_info>
  <brief_title>Vaginal Cuff Brachytherapy Followed by Chemotherapy in Endometrial Cancer</brief_title>
  <official_title>Phase II Trial of Vaginal Cuff Brachytherapy Followed by Adjuvant Chemotherapy With Carboplatin and Dose Dense Paclitaxel in Patients With High-Risk Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the feasibility of treatment in patients with high&#xD;
      risk endometrial cancer treated by vaginal cuff brachytherapy followed by 3 cycles of dose&#xD;
      dense paclitaxel and carboplatin chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Before the patient begins the study:&#xD;
&#xD;
      Endometrial cancer is commonly treated with surgery. The patient must have already had&#xD;
      surgery including hysterectomy (removal of the uterus) prior to being considered eligible for&#xD;
      this study. The surgery may also include removal of pelvic and para-aortic lymph nodes.&#xD;
      Following the surgery, the doctor will identify if the patient has factors related to the&#xD;
      cancer which places the patient at a greater risk for the cancer returning.&#xD;
&#xD;
      Prior to participating in this study there are exams, tests or procedures to find out if the&#xD;
      patient can be treated in the study. Most are part of regular cancer care.&#xD;
&#xD;
      Treatment:&#xD;
&#xD;
      All patients will receive radiation therapy followed by three cycles of dose dense paclitaxel&#xD;
      and carboplatin chemotherapy. Radiation therapy will be delivered either by LDR or HDR&#xD;
      brachytherapy and must be specified at the time of enrollment. The vaginal brachytherapy&#xD;
      should be started within 12 weeks of surgery (within 2 weeks of enrollment). Chemotherapy&#xD;
      should start within 3 weeks of initiating brachytherapy.&#xD;
&#xD;
      Study participation will be up to two years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 2, 2017</start_date>
  <completion_date type="Anticipated">December 13, 2022</completion_date>
  <primary_completion_date type="Actual">December 13, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Completing the Protocol</measure>
    <time_frame>4 months</time_frame>
    <description>Defined as completion of vaginal cuff brachytherapy followed by 3 cycles of dose dense paclitaxel and carboplatin chemotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of Adverse Events Related to Acute Toxicity During Treatment</measure>
    <time_frame>4 months</time_frame>
    <description>Frequency and severity of adverse events as assessed by the CTCAE v4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sites of Failure</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Proportion of participants who recur in regional versus distant recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free Survival</measure>
    <time_frame>up to 2 years</time_frame>
    <description>time from study entry to the first tumor recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contributing Cause of Death</measure>
    <time_frame>up to 2 years</time_frame>
    <description>The contributing cause of death for patients with high risk endometrial cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 2 years</time_frame>
    <description>time from study entry to death</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Endometrial Cancer</condition>
  <condition>Papillary Serous</condition>
  <condition>Clear Cell Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>Vaginal Cuff Brachytherapy + Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vaginal cuff brachytherapy followed by Carboplatin (AUC 6) on day 1and Paclitaxel 80 mg/m2 IV over 1 hour days 1, 8, and 15 X 3 total cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Vaginal Cuff Brachytherapy</intervention_name>
    <description>Within 12 weeks of surgery. Either LDR or HDR brachytherapy will be permitted</description>
    <arm_group_label>Vaginal Cuff Brachytherapy + Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin IV on day 1 of a 21 day cycle for 3 cycles</description>
    <arm_group_label>Vaginal Cuff Brachytherapy + Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel IV on days 1,8 and 15 of a 21 day cycle for 3 cycles</description>
    <arm_group_label>Vaginal Cuff Brachytherapy + Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. All patients must have undergone hysterectomy. Bilateral salpingooophorectomy is&#xD;
             strongly encouraged but not mandatory.&#xD;
&#xD;
          2. Pelvic and para-aortic lymphadenectomy are optional, but strongly encouraged.&#xD;
             Peritoneal washing are optional.&#xD;
&#xD;
          3. If either a bilateral salpingo-oophorectomy or nodal dissection was not performed,&#xD;
             post-operative pre-treatment CT/MRI is required and must not demonstrate evidence&#xD;
             suggestive of metastatic disease (adnexa, nodes, intraperitoneal disease).&#xD;
             Post-operative, pre-treatment CT/MRI must be performed if a pelvic and para-aortic&#xD;
             nodal dissection was not performed.&#xD;
&#xD;
          4. All patients will be staged according to the FIGO 2009 staging system and with&#xD;
             endometrial carcinoma (endometrioid types) confined to the corpus uteri or with&#xD;
             endocervical glandular involvement fitting one of the following high-intermediate risk&#xD;
             factor categories:&#xD;
&#xD;
               -  age ≥18 years with 3 risk factors&#xD;
&#xD;
               -  Risk factors:&#xD;
&#xD;
                    1. Grade 2 or 3 tumor, (+) lymphovascular space invasion, outer ½ myometrial&#xD;
                       invasion. Patients with these risk criteria may be enrolled with either&#xD;
                       positive or negative cytology.&#xD;
&#xD;
                    2. Patients with Stage II endometrial carcinoma (any histology) with cervical&#xD;
                       stromal invasion. (occult or gross involvement), with or without&#xD;
                       high-intermediate risk factors.&#xD;
&#xD;
                    3. Patients with serous or clear cell histology (with or without other&#xD;
                       high-intermediate risk factors) are eligible provided the disease is&#xD;
                       uterine-confined (with or without cervical stromal invasion or endocervical&#xD;
                       glandular involvement).&#xD;
&#xD;
          5. Patients must have GOG performance status 0, 1, or 2.&#xD;
&#xD;
          6. Patients must have adequate bone marrow, renal, hepatic and neurologic function per&#xD;
             protocol.&#xD;
&#xD;
          7. Patients who have met the pre-entry requirements specified in protocol; testing&#xD;
             values/results must meet eligibility criteria specified in protocol.&#xD;
&#xD;
          8. Patients must have signed an approved informed consent and authorization permitting&#xD;
             release of personal health information.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with recurrent disease.&#xD;
&#xD;
          2. Patients with GOG performance status of 3 or 4.&#xD;
&#xD;
          3. Greater than 12 weeks elapsed from surgery to enrollment.&#xD;
&#xD;
          4. Patients have prior pelvic or abdominal radiation therapy.&#xD;
&#xD;
          5. Known hypersensitivity to any component of study treatment that resulted in drug&#xD;
             discontinuation.&#xD;
&#xD;
          6. Significant intercurrent illness including, but not limited to, unstable angina&#xD;
             pectoris, and cardiac arrhythmia, or psychiatric illness/social situation that would&#xD;
             limit compliance with study requirements&#xD;
&#xD;
          7. Active pregnancy or lactation.&#xD;
&#xD;
          8. Prior malignancy requiring treatment within the last 3 years.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen Moore, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stephenson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 24, 2017</study_first_submitted>
  <study_first_submitted_qc>June 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2017</study_first_posted>
  <results_first_submitted>December 15, 2020</results_first_submitted>
  <results_first_submitted_qc>December 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 12, 2021</results_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endometrial Cancer</keyword>
  <keyword>Gynecologic Cancer</keyword>
  <keyword>radiation therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 4, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT03189446/Prot_SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 27, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT03189446/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited at a single institution from October 2017 to July 2019. The first patient was enrolled on October 2, 2017 and the last patient was enrolled on July 23, 2019</recruitment_details>
      <pre_assignment_details>Of 39 enrolled participants, 32 met inclusion criteria and evaluable then assign to the single arm treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Vaginal Cuff Brachytherapy + Chemotherapy</title>
          <description>Vaginal cuff brachytherapy followed by Carboplatin (AUC 6) on day 1and Paclitaxel 80 mg/m2 IV over 1 hour days 1, 8, and 15 X 3 total cycles&#xD;
Vaginal Cuff Brachytherapy: Within 12 weeks of surgery. Either LDR or HDR brachytherapy will be permitted&#xD;
Carboplatin: Carboplatin IV on day 1 of a 21 day cycle for 3 cycles&#xD;
Paclitaxel: Paclitaxel IV on days 1,8 and 15 of a 21 day cycle for 3 cycles</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vaginal Cuff Brachytherapy + Chemotherapy</title>
          <description>Vaginal cuff brachytherapy followed by Carboplatin (AUC 6) on day 1and Paclitaxel 80 mg/m2 IV over 1 hour days 1, 8, and 15 X 3 total cycles&#xD;
Vaginal Cuff Brachytherapy: Within 12 weeks of surgery. Either LDR or HDR brachytherapy will be permitted&#xD;
Carboplatin: Carboplatin IV on day 1 of a 21 day cycle for 3 cycles&#xD;
Paclitaxel: Paclitaxel IV on days 1,8 and 15 of a 21 day cycle for 3 cycles</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.5" lower_limit="41" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.1" lower_limit="24" upper_limit="68.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Completing the Protocol</title>
        <description>Defined as completion of vaginal cuff brachytherapy followed by 3 cycles of dose dense paclitaxel and carboplatin chemotherapy</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vaginal Cuff Brachytherapy + Chemotherapy</title>
            <description>Vaginal cuff brachytherapy followed by Carboplatin (AUC 6) on day 1and Paclitaxel 80 mg/m2 IV over 1 hour days 1, 8, and 15 X 3 total cycles&#xD;
Vaginal Cuff Brachytherapy: Within 12 weeks of surgery. Either LDR or HDR brachytherapy will be permitted&#xD;
Carboplatin: Carboplatin IV on day 1 of a 21 day cycle for 3 cycles&#xD;
Paclitaxel: Paclitaxel IV on days 1,8 and 15 of a 21 day cycle for 3 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Completing the Protocol</title>
          <description>Defined as completion of vaginal cuff brachytherapy followed by 3 cycles of dose dense paclitaxel and carboplatin chemotherapy</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Adverse Events Related to Acute Toxicity During Treatment</title>
        <description>Frequency and severity of adverse events as assessed by the CTCAE v4</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vaginal Cuff Brachytherapy + Chemotherapy</title>
            <description>Vaginal cuff brachytherapy followed by Carboplatin (AUC 6) on day 1and Paclitaxel 80 mg/m2 IV over 1 hour days 1, 8, and 15 X 3 total cycles&#xD;
Vaginal Cuff Brachytherapy: Within 12 weeks of surgery. Either LDR or HDR brachytherapy will be permitted&#xD;
Carboplatin: Carboplatin IV on day 1 of a 21 day cycle for 3 cycles&#xD;
Paclitaxel: Paclitaxel IV on days 1,8 and 15 of a 21 day cycle for 3 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Adverse Events Related to Acute Toxicity During Treatment</title>
          <description>Frequency and severity of adverse events as assessed by the CTCAE v4</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sites of Failure</title>
        <description>Proportion of participants who recur in regional versus distant recurrence</description>
        <time_frame>up to 2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrence-free Survival</title>
        <description>time from study entry to the first tumor recurrence</description>
        <time_frame>up to 2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Contributing Cause of Death</title>
        <description>The contributing cause of death for patients with high risk endometrial cancer</description>
        <time_frame>up to 2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>time from study entry to death</description>
        <time_frame>up to 2 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vaginal Cuff Brachytherapy + Chemotherapy</title>
          <description>Vaginal cuff brachytherapy followed by Carboplatin (AUC 6) on day 1and Paclitaxel 80 mg/m2 IV over 1 hour days 1, 8, and 15 X 3 total cycles&#xD;
Vaginal Cuff Brachytherapy: Within 12 weeks of surgery. Either LDR or HDR brachytherapy will be permitted&#xD;
Carboplatin: Carboplatin IV on day 1 of a 21 day cycle for 3 cycles&#xD;
Paclitaxel: Paclitaxel IV on days 1,8 and 15 of a 21 day cycle for 3 cycles</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Taxol Reaction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kathleen Moore</name_or_title>
      <organization>Stephenson Cancer Center</organization>
      <phone>405-271-8777</phone>
      <email>Kathleen-Moore@ouhsc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

